Sign in
CGEN Stock Price, Chart, Stats & News
Compugen Ltd.
Save
Compugen Ltd. (CGEN) does not currently pay a dividend.
220.31M
Market cap
6.13x
Current P/E
12.36x
Forward P/E
CGEN chart
Fundamentals
Gross margin | 87.29% |
Operating margin | 43.05% |
Pretax margin | 48.65% |
Net margin | 48.57% |
Effective tax rate | 0.15% |
ROA | 22.53% |
ROE | 55.68% |
D/E | 0.03x |
Interest coverage ratio | – |
CGEN valuation
P/E | 6.13x |
P/S | 2.65x |
P/B | 1.87x |
P/CF | 6.08x |
P/FCF | 6.16x |
P/OCF | 6.08x |
PEG | 0.02x |
EV multiple | 8.41x |
About
Compugen Ltd., an Israeli-based company established in 1993 and headquartered in Holon, is a clinical-stage enterprise focused on the discovery, development, and commercialization of therapeutic and product candidates. Its operations extend across Israel, the United States, and Europe. The company’s core activities center around its immuno-oncology pipeline, which includes several investigational treatments: COM701, an anti-PVRIG antibody currently undergoing Phase I clinical studies for solid tumors.
Similar securities
Based on sector and market capitalization
Report issue